The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback